Researchers push asthma into remission with one dose of CAR-T

Woman using an asthma inhaler

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study.

The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was published in Nature Immunology.

Type 2-high asthma is characterised by interleukin (IL)-5-driven eosinophilia, along with airway inflammation and remodelling caused by IL-4 and IL-13.

The research team, based in Beijing, China, utilised IL-5 as the targeting domain and deplete BCOR and ZC3H12A to engineer long-lived CAR-T cells that can eradicate eosinophils.

The so-called 5TIF cells were further modified to secrete an IL-4 mutein that blocks IL-4 and IL-13 signaling, designated as 5TIF4 cells.

The data showed that, in asthma models, a single infusion of 5TIF4 cells in fully immunocompetent mice, without any conditioning regimen, led to sustained repression of lung inflammation and alleviation of asthmatic symptoms.

Though only approved so far for the treatment of several cancers, CAR-T therapy is being explored in a number of other therapy areas. In April, the US Food and Drug Administration (FDA) authorised the first CAR-T clinical trial for children with systemic lupus erythematosus.

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free